Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q15485
UPID:
FCN2_HUMAN
Alternative names:
37 kDa elastin-binding protein; Collagen/fibrinogen domain-containing protein 2; EBP-37; Ficolin-B; Ficolin-beta; Hucolin; L-ficolin; Serum lectin p35
Alternative UPACC:
Q15485; A6NFG7; A8K478; Q6IS69; Q7M4P4; Q9UC57
Background:
Ficolin-2, also known as L-ficolin or Serum lectin p35, is a key player in innate immunity, recognized for its role in the lectin complement pathway. This calcium-dependent and GlcNAc-binding lectin is pivotal in enhancing the phagocytosis of S.typhimurium by neutrophils, indicating an opsonic effect through its collagen region. Its alternative names include 37 kDa elastin-binding protein, Collagen/fibrinogen domain-containing protein 2, and Ficolin-B, among others.
Therapeutic significance:
Understanding the role of Ficolin-2 could open doors to potential therapeutic strategies. Its involvement in innate immunity and the lectin complement pathway highlights its significance in developing treatments for infectious diseases.